BeOne Medicines AG (ONC)

BeOne Medicines AG Stock Forecast

Stock Price Forecast

The 11 analysts that cover BeOne Medicines AG stock have a consensus rating of "Strong Buy" and an average price target of $380.45, which forecasts a 26.39% increase in the stock price over the next year. The lowest target is $290 and the highest is $425.

Price Target: $380.45 (+26.39%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$290	$380.45	$396	$425
Change	-3.66%	+26.39%	+31.56%	+41.19%

* Price targets were last updated on Mar 27, 2026.

Analyst Ratings

The average analyst rating for BeOne Medicines AG stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26
Strong Buy	4	4	4	4	4	4
Buy	8	8	8	8	7	6
Hold	0	0	0	0	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	12	12	12	12	12	11

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Kalpit Patel Wolfe Research	Wolfe Research	Buy Initiates $340	Buy	Initiates	$340	+12.95%	Mar 27, 2026
Faisal Khurshid Jefferies	Jefferies	Strong Buy → Hold Downgrades $420 → $290	Strong Buy → Hold	Downgrades	$420 → $290	-3.66%	Mar 16, 2026
Leonid Timashev RBC Capital	RBC Capital	Buy Maintains $417 → $425	Buy	Maintains	$417 → $425	+41.19%	Feb 27, 2026
Gregory Renza Truist Securities	Truist Securities	Strong Buy Maintains $400 → $412	Strong Buy	Maintains	$400 → $412	+36.87%	Feb 27, 2026
Michael Schmidt Guggenheim	Guggenheim	Strong Buy Maintains $400 → $410	Strong Buy	Maintains	$400 → $410	+36.21%	Feb 27, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

45.27B

Increased by 747.23%

from 5.34B

Revenue Next Year

52.41B

Increased by 15.78%

from 45.27B

EPS This Year

3.30

Increased by 33.64%

from 2.47

EPS Next Year

4.86

Increased by 47.12%

from 3.30

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	1.18B	1.42B	2.46B	3.81B	5.34B	45.27B	52.41B
Revenue Growth	280.83%	20.37%	73.65%	54.97%	40.23%	747.23%	15.78%
EPS	-15.71	-19.43	-8.45	-6.12	2.47	3.30	4.86
EPS Growth	-	-	-	-	-	33.64%	47.12%
Forward PE	-	-	-	-	-	91.19	61.98
No. Analysts	-	-	-	-	-	9	9

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030	2031	2032	2033
High	48.6B	59.8B
Avg	45.3B	52.4B
Low	42.0B	46.6B

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	809.5%	32.2%
Avg	747.2%	15.8%
Low	686.5%	3.0%

EPS Forecast

EPS	2026	2027	2028	2029	2030	2031	2032	2033
High	3.84	7.07
Avg	3.30	4.86
Low	2.90	2.93

EPS Growth

EPS Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	55.6%	114.1%
Avg	33.6%	47.1%
Low	17.4%	-11.2%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.